List of Excipients in Branded Drug MEPIVACAINE

« Back to Dashboard

Generic Drugs Containing MEPIVACAINE

Company	Ingredient	NDC	Excipient
NDC Inc	mepivacaine hydrochloride	43128-005	SODIUM CHLORIDE
NDC Inc	mepivacaine hydrochloride	43128-005	WATER
Patterson Dental Supply Inc	mepivacaine hydrochloride	50227-1080	SODIUM CHLORIDE
Patterson Dental Supply Inc	mepivacaine hydrochloride	50227-1080	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in MEPIVACAINE?

# Of NDCs	Excipient
6	SODIUM CHLORIDE
3	SODIUM HYDROXIDE
6	WATER

Mepivacaine Excipient Strategy and Commercial Opportunities

Last updated: October 14, 2026

Mepivacaine is a mature amide local anesthetic with limited basic-molecule exclusivity and substantial generic competition. Commercial value is concentrated in formulation execution: preservative-free sterile injections, dental cartridges, ready-to-use presentations, pH and osmolality control, low-waste packaging, and differentiated delivery systems. The strongest opportunities are likely to come from manufacturing reliability, device compatibility, supply continuity, and specialty formulations rather than from new chemical-entity protection.

What is the FDA regulatory status of mepivacaine?

Mepivacaine is an FDA-recognized local anesthetic marketed primarily as mepivacaine hydrochloride injection. It is used for local or regional anesthesia in dental, infiltration, peripheral nerve block, and selected epidural or caudal procedures, depending on the product label.

Common presentations include:

Presentation	Typical strength	Primary market
Mepivacaine hydrochloride injection	1%, 1.5%, 2%, 3%	Hospital, ambulatory surgery, dental
Dental cartridge	2%	Dentistry
Dental cartridge, plain	3%	Dentistry
Mepivacaine with vasoconstrictor	2% with levonordefrin in certain legacy products	Dentistry

Mepivacaine is supplied as a hydrochloride salt because the salt form improves aqueous solubility and enables sterile injectable products. FDA-approved products are generally prescription products regulated through the abbreviated new drug application pathway or legacy approval pathways rather than through current new-drug exclusivity.

The FDA’s Inactive Ingredient Database is relevant to excipient selection because an excipient with prior precedent in an injectable or dental dosage form has a lower regulatory risk profile than a novel excipient or an unqualified concentration range.[1]

What excipients are used in mepivacaine injections?

The simplest mepivacaine injectable formulation uses water for injection as the vehicle, with sodium chloride for tonicity and hydrochloric acid or sodium hydroxide for pH adjustment where required. Some products may have minimal excipient loads because mepivacaine hydrochloride is sufficiently water-soluble.

Typical excipient categories are:

Excipient category	Candidate materials	Commercial purpose
Vehicle	Water for injection	Dissolves active ingredient
Tonicity agent	Sodium chloride	Reduces injection-site discomfort and supports physiological osmolality
pH adjuster	Hydrochloric acid, sodium hydroxide	Controls stability, solubility, and tolerability
Antioxidant	Sodium metabisulfite or related sulfite	Used primarily in formulations containing a vasoconstrictor susceptible to oxidation
Chelator	Disodium edetate	May reduce metal-catalyzed oxidation where justified
Preservative	Benzyl alcohol, chlorobutanol, or other approved preservative	Multidose-container protection, subject to route and patient-population limits

Preservatives are less attractive for single-dose neuraxial or injection products. A preservative-free formulation can carry a commercial advantage in anesthesia settings because preservative exposure is a concern for epidural, caudal, intrathecal-adjacent, pediatric, and ophthalmic use cases. The label, route, container and closure system determine whether an excipient is acceptable.

How does the formulation differ between plain and vasoconstrictor products?

Plain mepivacaine products can be relatively simple aqueous solutions. Products containing levonordefrin or another vasoconstrictor require tighter control of oxidation, light exposure, oxygen ingress, and trace metals.

A vasoconstrictor formulation may require:

• An antioxidant such as sodium metabisulfite.
• Light-protective primary packaging.
• Controlled headspace oxygen.
• Compatibility testing with rubber closures, aluminum seals, and cartridge glass.
• Stability studies for color change and potency loss.
• Careful evaluation of sulfite sensitivity labeling.

This difference creates a formulation opportunity. A manufacturer that develops a stable, preservative-free, low-oxygen cartridge system may differentiate a mepivacaine product without changing the active ingredient.

What formulations are commercially attractive for mepivacaine?

Preservative-free multidose alternatives

Mepivacaine is normally associated with single-dose vials, ampoules, or dental cartridges. A preservative-free multidose presentation using a validated sterile barrier or dose-delivery system could reduce waste in high-volume settings.

Potential platforms include:

• Unit-dose polymer ampoules.
• Blow-fill-seal containers.
• Prefilled syringes.
• Cartridge-based systems.
• Multidose systems with microbial-barrier valves.

The principal regulatory burden is container-closure integrity and aseptic process validation. The formulation itself may require few excipients, but the device and fill-finish process become central intellectual-property assets.

Ready-to-use diluted products

Hospitals often dilute local anesthetics for specific blocks or infusion protocols. Ready-to-use concentrations could reduce preparation errors and pharmacy labor.

Potential strengths include:

• 0.5%.
• 0.75%.
• 1%.
• 1.5%.
• 2%.

The business case depends on clinical demand, shelf life, bag or syringe compatibility, and whether the product can be supplied without preservatives. A ready-to-use product may obtain a stronger commercial position than a standard vial if it reduces preparation steps and medication errors.

Buffered mepivacaine

Buffering can reduce injection discomfort and may influence onset characteristics, but it also creates stability and precipitation risks. Candidate buffers include bicarbonate or phosphate systems, although the selected buffer must be evaluated against pH drift, carbon dioxide exchange, ionic strength, and compatibility with the hydrochloride salt.

A buffered formulation requires testing for:

• Immediate and accelerated stability.
• Precipitation after dilution.
• Sterility through the labeled shelf life.
• Compatibility with syringes and needles.
• Potency after contact with common infusion materials.
• Changes in onset, duration, and injection pain.

Buffering is more defensible as a formulation strategy when linked to a defined clinical use, such as dental injection comfort or rapid onset in peripheral nerve blocks.

Sustained-release mepivacaine

Long-acting local anesthesia is a larger commercial opportunity but also a more difficult technical target. Candidate technologies include liposomes, biodegradable microspheres, in situ gels, polymer depots, and injectable hydrogels.

Mepivacaine is less commercially differentiated than bupivacaine or ropivacaine in extended-duration anesthesia. A sustained-release mepivacaine product would need to establish a clear benefit in duration, motor-sparing effect, safety, or recovery profile.

Key development barriers include:

• Burst release.
• Local tissue toxicity.
• Polymer residuals.
• Sterilization.
• Dose uniformity.
• Injection-force requirements.
• Removal of residual solvent.
• Reproducibility of particle size and drug loading.

A depot product could support composition-of-matter, formulation, process, and method-of-use patent claims. It would also face a higher clinical and regulatory burden than a conventional generic injection.

How strong is the patent estate for mepivacaine?

The core mepivacaine molecule is mature, and commercial products are generally exposed to generic competition. The principal patent opportunity is therefore not basic-molecule exclusivity. It is secondary protection around a specific product architecture.

Potentially protectable subject matter includes:

Patent area	Example claim strategy	Relative value
Composition	Mepivacaine with a defined buffer, antioxidant, chelator, or polymer	Moderate
Concentration	Narrow concentration and pH ranges linked to stability or tolerability	Moderate
Delivery system	Prefilled syringe, cartridge, multidose valve, or depot injector	Moderate to high
Manufacturing	Low-oxygen filling, sterilization, particle-size control, or aseptic process	Moderate
Method of use	Specific nerve block, dental procedure, dosing regimen, or patient subgroup	Moderate
Combination product	Mepivacaine with vasoconstrictor, anti-inflammatory, or adjunctive agent	Moderate
Basic active ingredient	Mepivacaine itself	Low

Patent strength depends on whether the claimed excipient combination produces an unexpected technical result. A claim covering "mepivacaine plus sodium chloride in water" would likely face substantial obviousness and prior-art challenges. A claim directed to a narrow, demonstrated stability profile in a particular container system would be more defensible.

What is the Orange Book status of mepivacaine?

Mepivacaine should be analyzed at the product level rather than as a single Orange Book asset. Different manufacturers, strengths, dosage forms, and routes may have different listing histories.

For most mature mepivacaine products, the expected competitive structure is:

1. A reference or legacy product.
2. Multiple generic or abbreviated-approval products.
3. Limited remaining market exclusivity.
4. Competition based on supply, packaging, contract pricing, and distribution.

Orange Book analysis should confirm:

• Active ingredient and dosage form.
• Listed reference product.
• Strength and route.
• Patent listings, if any.
• Generic application approvals.
• Therapeutic-equivalence codes.
• Discontinued or withdrawn status.
• Any product-specific exclusivity.

FDA Orange Book data and Drugs@FDA records are the controlling sources for current listing and approval information.[2,3] No broad conclusion about an active Orange Book patent should be made from the drug name alone.

When does mepivacaine lose exclusivity?

Mepivacaine’s principal commercial exclusivity has already eroded through decades of clinical use and generic supply. The relevant question for a new entrant is not when the active ingredient loses exclusivity, but whether a particular formulation, device, manufacturing process, or method of use has enforceable secondary protection.

A conventional mepivacaine hydrochloride injection is unlikely to support meaningful new chemical-entity exclusivity. A new product could still obtain regulatory protection or commercial differentiation through:

• A novel drug-delivery system.
• A new dosage form.
• A pediatric or specialty indication.
• A clinically differentiated sustained-release product.
• A device-drug combination.
• Orphan-drug status, if a qualifying rare-disease indication existed.

Any proposed product must also account for patent term adjustment, patent-term extension, obviousness-type double-patenting, terminal disclaimers, and prosecution history. These issues are particularly important for narrow excipient claims, which can be vulnerable to obviousness attacks if the formulation lacks comparative data.

What Paragraph IV challenges and litigation affect mepivacaine?

Paragraph IV risk is generally lower for a mature, non-innovator local anesthetic than for a recently approved branded drug. The main litigation exposure for a new mepivacaine product would more likely arise from:

• A patented sustained-release formulation.
• A cartridge or syringe device.
• A combination with a vasoconstrictor.
• A manufacturing process.
• A method-of-use patent.
• Trade-secret disputes involving sterile manufacturing or fill-finish processes.

A standard ANDA applicant could challenge listed patents through Paragraph IV certification if applicable patents appear in the Orange Book. For an unlisted formulation or device patent, litigation could arise under the Hatch-Waxman framework, the Patent Act, or contract and trade-secret law depending on the product design.

Settlement agreements should be evaluated for:

• Authorized generic provisions.
• Delayed launch dates.
• Supply commitments.
• Patent-license scope.
• Geographic limitations.
• Restrictions on formulation or packaging.
• Acceleration clauses if the patent is invalidated.

Public litigation databases, FDA records, SEC filings, and court dockets should be checked for product-specific activity. A mepivacaine diligence review should not infer litigation risk from litigation involving bupivacaine, ropivacaine, lidocaine, or other local anesthetics.

Which companies are challenging or competing with mepivacaine?

Competition is fragmented across generic injectable manufacturers, dental anesthetic suppliers, contract manufacturers, and hospital-distribution channels. Relevant competitors may include companies selling:

• Mepivacaine hydrochloride injection.
• Lidocaine hydrochloride.
• Bupivacaine hydrochloride.
• Ropivacaine hydrochloride.
• Articaine hydrochloride for dentistry.
• Prilocaine-containing dental products.
• Liposomal bupivacaine for extended-duration use.

Mepivacaine’s strongest competitive position is in dentistry and procedures requiring an intermediate-duration, amide local anesthetic without the same degree of prolonged motor block associated with some alternatives. Its disadvantages include limited differentiation in standard vials and price pressure from generic local anesthetics.

How does mepivacaine compare with competing local anesthetics?

Attribute	Mepivacaine	Lidocaine	Bupivacaine	Ropivacaine	Articaine
Core use	Dental and regional anesthesia	Broad local anesthesia	Longer regional anesthesia	Regional anesthesia	Dentistry
Generic maturity	High	High	High	High	Moderate to high
Formulation complexity	Low to moderate	Low to moderate	Low to moderate	Low to moderate	Dental-focused
Extended-release opportunity	Moderate	Moderate	High	Moderate	Low to moderate
Dental relevance	High	High	Lower	Low	High
Differentiation potential	Packaging, preservative-free use, delivery	Broad indication coverage	Duration and depot technology	Motor-sparing positioning	Dental onset and infiltration

Bupivacaine has a larger sustained-release commercial precedent, while articaine has stronger dental specialization. Mepivacaine’s opportunity is a focused product with operational advantages rather than a direct attempt to displace long-acting premium anesthetics.

What manufacturing and excipient barriers affect commercialization?

The main manufacturing barriers are sterile processing, low bioburden control, container-closure integrity, and supply consistency. Excipient sourcing is relatively straightforward for sodium chloride and water for injection, but supply risk can arise from:

• Sterile-grade packaging shortages.
• Glass or polymer cartridge availability.
• Rubber closure extractables and leachables.
• Sulfite or antioxidant variability.
• Drug-substance particle or assay variability.
• Fill-finish capacity.
• Regulatory changes affecting preservatives or single-use plastics.

For dental cartridges, glass dimensional tolerances, plunger movement, crimp integrity, and compatibility with dental aspirating syringes are commercial-critical attributes. A product that performs well chemically but has inconsistent aspiration or leakage can lose market access.

What licensing deals could create value?

Mepivacaine licensing opportunities are more likely to involve technology than the active ingredient. Attractive deal structures include:

• Licensing a sustained-release platform for local anesthetics.
• Acquiring a sterile cartridge or prefilled-syringe platform.
• Co-developing a preservative-free multidose system.
• Partnering with a dental distributor for private-label supply.
• Licensing a low-oxygen fill-finish process.
• Combining mepivacaine with a proprietary adjunct or device.

A license should define ownership of formulation improvements, process changes, regulatory correspondence, stability data, device modifications, and manufacturing know-how. Territory should be separated by dosage form because dental cartridges, hospital injections, and depot products have different commercial channels.

What revenue exposure exists for mepivacaine products?

Revenue exposure is driven by unit volume rather than high price per dose. Standard mepivacaine injection is vulnerable to tender pricing and substitution. Higher-value opportunities are concentrated in:

• Dental cartridge supply.
• Shortage-resistant hospital presentations.
• Ready-to-use syringes.
• Specialty procedural kits.
• Premium packaging with lower preparation waste.
• Extended-release or combination products.

The most defensible commercial thesis is a reliable, preservative-free, ready-to-use product with validated device compatibility and a differentiated supply position. A basic vial with conventional excipients would likely compete mainly on cost.

Key Takeaways

• Mepivacaine is a mature generic local anesthetic with limited basic-molecule exclusivity.
• The standard formulation can use a low excipient load, typically water for injection, sodium chloride, and pH adjusters.
• Vasoconstrictor products require stronger oxidation, light, oxygen, and sulfite controls.
• The best near-term opportunities are preservative-free presentations, dental cartridges, ready-to-use syringes, and supply-reliable sterile products.
• Sustained-release mepivacaine has higher upside but requires substantial clinical, formulation, device, and patent investment.
• Patent value is most likely to come from delivery systems, narrow stability claims, manufacturing processes, and defined methods of use.
• Orange Book and Paragraph IV conclusions must be made at the individual product and dosage-form level.
• Commercial differentiation depends more on packaging, fill-finish quality, distribution, and clinical workflow than on conventional excipient selection.

FAQs

Is mepivacaine compatible with sodium chloride injection?

Mepivacaine hydrochloride is generally formulated as an aqueous solution, and sodium chloride may be used as a tonicity agent. Compatibility must be confirmed for the specific concentration, container, dilution medium, storage period, and administration route.

Does mepivacaine require a preservative?

No. Single-dose mepivacaine products can be preservative-free. Preservatives may be considered for multidose presentations, but route, patient population, container design, and regulatory precedent limit the available choices.

Can mepivacaine be formulated with epinephrine?

Mepivacaine may be combined with a vasoconstrictor in certain dental products, although legacy products may use levonordefrin rather than epinephrine. The combination requires antioxidant, oxygen-control, light-protection, and stability evaluation.

Is a mepivacaine liposomal formulation commercially attractive?

It could be attractive if it provides a clinically meaningful extension of analgesia with acceptable motor effects and local tolerability. The product would face higher development costs and a more complex regulatory pathway than a conventional injectable.

What is the strongest patent strategy for a new mepivacaine product?

The strongest strategy would typically combine formulation claims with device, process, and method-of-use claims. Claims should be supported by comparative stability, injection comfort, release, compatibility, or clinical data rather than by routine excipient substitution alone.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
4. U.S. National Library of Medicine. (n.d.). DailyMed: Mepivacaine hydrochloride injection labels. https://dailymed.nlm.nih.gov/dailymed/
5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.